VLP stands for virus-like particles. Virus-like particles are molecules that mimic viruses but are not infectious. They are a very effective way of creating vaccines against diseases such as human ...
VANCOUVER, BRITISH COLUMBIA, CANADA, May 14, 2026 / EINPresswire.com / — Renaissance BioScience Corp., a global leader in bioengineered yeast, today announced the filing of a provisional patent ...
3 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces further investment in virus-like particle ...
Icosavax has drawn up clinical trial plans for its new type of vaccine in a strategy to commence tests of multiple programs, including a Covid-19 candidate. But really, the startup is following a path ...
Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed ...
Wataru Akahata, CEO of VLP Therapeutics Japan LLC, thinks he can help provide a solution to the challenge of securing COVID-19 vaccines for billions of people — the development of a second-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results